Skip to content

Analysis of Medication Patterns in the Combined Use of Traditional Chinese Medicine and Western Medicine for Pediatric Bronchopneumonia Based on HIS-Associated Rules

Analysis of Medication Patterns in the Combined Use of Traditional Chinese Medicine and Western Medicine for Pediatric Bronchopneumonia Based on HIS-Associated Rules

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128790
Enrollment
Unknown
Registered
2026-07-26
Start date
2025-09-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Bronchopneumonia

Interventions

Observation group:None

Sponsors

Guangdong Province Hospital for Women and Children Healthcare
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 14 Years

Inclusion criteria

Inclusion criteria: 1. Age: <=14 years old (covering infants, preschoolers, and school-age children, which is consistent with the population characteristics of high incidence of pediatric bronchopneumonia); 2. Medical Institution and Diagnostic Requirements: Having sought medical treatment at Guangdong Women and Children Hospital from January 2022 to July 2025, with a clear Western medical diagnosis of "pediatric bronchopneumonia" and complete TCM syndrome diagnosis; 3. Treatment and Medical Record Requirements: Having received combined treatment of "TCM herbal compatibility combinations + Western medicines", with complete medication details (composition of TCM prescriptions, types of Western medicines) recorded in the Hospital Information System (HIS); 4. Baseline Information Requirements: Having complete baseline information (including name, gender, age, diagnosis and treatment date, etc.).

Exclusion criteria

Exclusion criteria: 1. Unclear or ambiguous TCM syndrome diagnosis (e.g., only labeled as "pneumonia" without specifying the syndrome type); 2. Use of only proprietary Chinese medicines (PCMs) and Western medicines in the treatment regimen (excluding TCM herbal compatibility combinations); 3. Age >14 years old (beyond the scope of pediatric population, with significant differences in physiological and pathological characteristics from children); 4. Comorbidity with important organ damage (such as heart failure, hepatic or renal failure) or other severe underlying diseases (such as congenital heart disease, immunodeficiency diseases); 5. Missing case data (e.g., incomplete medication records, missing baseline information) or existing logical errors (e.g., contradictions between medication dates and diagnosis/treatment dates).

Design outcomes

Primary

MeasureTime frame
Outcome Variable Indicators (Measurement of Association Rules and Medication Patterns);

Countries

China

Contacts

Public ContactKaili Liu

Guangdong Province Hospital for Women and Children Healthcare

hellelau@163.com+86 20 39151711

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026